Who
Fred Hassan
Director
Company insider
Files Form 4 as: Director, BridgeBio Pharma; Director, Precigen; Director, Cocrystal Pharma; Director, EyePoint; Director, Prometheus Biosciences; Director, Amgen; Director, Warner Media; Director, Bausch Health Companies.
In numbers
- Trades disclosed
- 185
- Buys
- 7
- Sells
- 0
- Bought
- $10.0M
- Sold
- $0
- Companies
- 10
- Companies where not an officer
- 9
- First trade
- 4 May 2006
- Last trade
- 22 Jun 2026
- Last filed
- 24 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 22 Jun 2026filed 24 Jun 2026 | BBIO BridgeBio PharmaBiotechnology | SEC FORM 4 Code A | —3,990 at $0.00 | filing |
| 22 Jun 2026filed 24 Jun 2026 | BBIO BridgeBio Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —5,277 at $0.00 | filing |
| 22 Jun 2026filed 24 Jun 2026 | BBIO BridgeBio Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —5,277 at $0.00 | filing |
| 22 Jun 2026filed 24 Jun 2026 | BBIO BridgeBio PharmaBiotechnology | SEC FORM 4 Code A | —3,990 at $0.00 | filing |
| 13 Mar 2026filed 16 Mar 2026 | PGEN PrecigenBiotechnology | SEC FORM 4 Code M | —71,839 | filing |
| 13 Mar 2026filed 16 Mar 2026 | PGEN Precigenoption or derivative · Biotechnology | SEC FORM 4 Code M | —71,839 at $0.00 | filing |
| 13 Mar 2026filed 16 Mar 2026 | PGEN Precigenoption or derivative · Biotechnology | SEC FORM 4 Code M | —71,839 at $0.00 | filing |
| 13 Mar 2026filed 16 Mar 2026 | PGEN PrecigenBiotechnology | SEC FORM 4 Code M | —71,839 | filing |
| 10 Mar 2026filed 12 Mar 2026 | PGEN PrecigenBiotechnology | SEC FORM 4 Code A | $63K17,948 at $3.51 | filing |
| 10 Mar 2026filed 12 Mar 2026 | PGEN Precigenoption or derivative · Biotechnology | SEC FORM 4 Code A | —35,612 at $0.00 | filing |
| 10 Mar 2026filed 12 Mar 2026 | PGEN Precigenoption or derivative · Biotechnology | SEC FORM 4 Code A | —41,073 at $0.00 | filing |
| 10 Mar 2026filed 12 Mar 2026 | PGEN Precigenoption or derivative · Biotechnology | SEC FORM 4 Code A | —35,612 at $0.00 | filing |
| 10 Mar 2026filed 12 Mar 2026 | PGEN Precigenoption or derivative · Biotechnology | SEC FORM 4 Code A | —41,073 at $0.00 | filing |
| 10 Mar 2026filed 12 Mar 2026 | PGEN PrecigenBiotechnology | SEC FORM 4 Code A | $63K17,948 at $3.51 | filing |
| 9 Jan 2026filed 13 Jan 2026 | COCP Cocrystal Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —16,410 at $0.00 | filing |
| 9 Jan 2026filed 13 Jan 2026 | COCP Cocrystal Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —16,410 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | EYPT EyePointoption or derivative · Biotechnology | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | EYPT EyePointoption or derivative · Biotechnology | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
| 28 Oct 2025filed 30 Oct 2025 | COCP Cocrystal Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | $1.0M719,426 at $1.39 | filing |
| 28 Oct 2025filed 30 Oct 2025 | COCP Cocrystal PharmaBiotechnology | SEC FORM 4 Code A | $500K359,713 at $1.39 | filing |
News
Contrasting Merck & Co., Inc. (NYSE:MRK) and ABVC BioPharma (NASDAQ:ABVC)MRK · themarketsdaily.com · 21 Oct 2026Amgen vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026?AMGN · fool.com · 20 Oct 2026AMGEN TO PRESENT AT THE EUROPEAN SOCIETY OF MEDICAL ONCOLOGY CONGRESS 2026AMGN · prnewswire.com · 20 Oct 2026Merck (MRK) Has New Cancer Treatments. Can They Outgrow the Keytruda Patent Cliff?MRK · insidermonkey.com · 20 Oct 2026BridgeBio Pharma (NASDAQ:BBIO) Given New $91.00 Price Target at CitigroupBBIO · dailypolitical.com · 19 Oct 2026Merck's 2.4% Dividend Yield: A Reliable Income Stream or a Risky Bet on Recovery?MRK · insidermonkey.com · 19 Oct 2026Amgen Has the Drugs and the Dividend. Now It Needs the GrowthAMGN · insidermonkey.com · 19 Oct 2026Contrasting Ocular Therapeutix (NASDAQ:OCUL) and Bausch Health Cos (NYSE:BHC)BHC · dailypolitical.com · 13 Oct 2026
0 headlines in the last 90 days name Fred Hassan; 9 articles from the last 14 days about the 5 companies they traded most, at most three about any one of them.